Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer.

Matuszewska K, Santry LA, van Vloten JP, AuYeung AWK, Major PP, Lawler J, Wootton SK, Bridle BW, Petrik J.

Clin Cancer Res. 2019 Mar 1;25(5):1624-1638. doi: 10.1158/1078-0432.CCR-18-0220. Epub 2018 Sep 11.

PMID:
30206160
2.

Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer.

Santry LA, McAusland TM, Susta L, Wood GA, Major PP, Petrik JJ, Bridle BW, Wootton SK.

Mol Ther Methods Clin Dev. 2017 Oct 16;9:181-191. doi: 10.1016/j.omtm.2017.10.004. eCollection 2018 Jun 15.

3.

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM; NRG Oncology RTOG.

N Engl J Med. 2017 Feb 2;376(5):417-428. doi: 10.1056/NEJMoa1607529.

4.

Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.

Westdorp H, Sköld AE, Snijer BA, Franik S, Mulder SF, Major PP, Foley R, Gerritsen WR, de Vries IJ.

Front Immunol. 2014 May 6;5:191. doi: 10.3389/fimmu.2014.00191. eCollection 2014. Review.

5.

Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials.

Coleman RE, Lipton A, Costa L, Cook RJ, Lee KA, Saad F, Brown JE, Terpos E, Major PP, Kohno N, Smith M, Body JJ.

J Bone Oncol. 2013 Feb 9;2(2):70-6. doi: 10.1016/j.jbo.2013.01.002. eCollection 2013 Jun.

6.

Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity.

Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE.

BMC Cancer. 2009 Aug 6;9:272. doi: 10.1186/1471-2407-9-272.

7.

Effect of bisphosphonates on pain and quality of life in patients with bone metastases.

Costa L, Major PP.

Nat Clin Pract Oncol. 2009 Mar;6(3):163-74. doi: 10.1038/ncponc1323. Epub 2009 Feb 3. Review.

PMID:
19190592
8.

Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic Acid in patients with bone metastases from solid tumors.

Major PP, Cook RJ, Chen BL, Zheng M.

Support Cancer Ther. 2005 Jul 1;2(4):234-40. doi: 10.3816/SCT.2005.n.017.

PMID:
18628179
9.

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.

Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE.

J Thorac Oncol. 2008 Mar;3(3):228-36. doi: 10.1097/JTO.0b013e3181651c0e.

10.

An optimized clinical regimen for the oncolytic virus PV701.

Hotte SJ, Lorence RM, Hirte HW, Polawski SR, Bamat MK, O'Neil JD, Roberts MS, Groene WS, Major PP.

Clin Cancer Res. 2007 Feb 1;13(3):977-85.

11.

A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer.

Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, Major PP, Miller WH Jr, Panasci L, Lorimer IA, Batist G, Matthews S, Douglas L, Seymour L.

Invest New Drugs. 2005 Mar;23(2):165-70.

PMID:
15744593
12.

Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.

Lorence RM, Pecora AL, Major PP, Hotte SJ, Laurie SA, Roberts MS, Groene WS, Bamat MK.

Curr Opin Mol Ther. 2003 Dec;5(6):618-24. Review.

PMID:
14755888
13.
14.
15.

Oral bisphosphonates: A review of clinical use in patients with bone metastases.

Major PP, Lipton A, Berenson J, Hortobagyi G.

Cancer. 2000 Jan 1;88(1):6-14. Review.

PMID:
10618600
16.

Quantitative dot blot analyses of blood-group-related antigens in paired normal and malignant human breast tissues.

Ura Y, Dion AS, Williams CJ, Olsen BD, Redfield ES, Ishida M, Herlyn M, Major PP.

Int J Cancer. 1992 Jan 2;50(1):57-63.

PMID:
1728614
17.

Recognition of peptidyl epitopes by polymorphic epithelial mucin (PEM)-specific monoclonal antibodies.

Dion AS, Smorodinsky NI, Williams CJ, Wreschner DH, Major PP, Keydar I.

Hybridoma. 1991 Oct;10(5):595-610.

PMID:
1804772
18.

Breast tumor radioimmunodetection with a 111In-labeled monoclonal antibody (MA5) against a mucin-like antigen.

Major PP, Dion AS, Williams CJ, Mattes MJ, Wang T, Rosenthall L.

Cancer Res. 1990 Feb 1;50(3 Suppl):927s-931s.

19.

Patterns of antigen distribution in human carcinomas.

Mattes MJ, Major PP, Goldenberg DM, Dion AS, Hutter RV, Klein KM.

Cancer Res. 1990 Feb 1;50(3 Suppl):880s-884s.

20.
21.
22.

Double antibody radioimmunoassay for monitoring metastatic breast cancer.

Schecter RL, Major PP, Kovac PE, Ishida M, Kovalik EC, Dion AS, Langleben A, Boileau G, Boos G, Panasci L, et al.

Br J Cancer. 1988 Sep;58(3):362-7.

23.

Tumor-associated antigens as immunotherapy targets.

Phillips NC, Major PP, Sikorska H.

Cancer Detect Prev. 1988;12(1-6):451-9.

PMID:
3263200
24.

Liposomal incorporation and immunogenicity of carcinoembryonic antigen.

Phillips NC, Major PP, Ishida M, Sikorska H.

J Biol Response Mod. 1987 Dec;6(6):581-6.

PMID:
3450782
25.

Cellular heterogeneity in normal and neoplastic human urothelium: a study using murine monoclonal antibodies.

Dotsikas G, Konowalchuk T, Major PP, Kovac PE, Ward GK, Stewart SS, Price GB, Elhilali MM, Mackillop WJ.

Br J Cancer. 1987 Oct;56(4):439-44.

26.

Monoclonal antibodies to antigens abnormally expressed in breast cancer.

Major PP, Kovac PE, Lavallée ML, Kovalik EC.

J Histochem Cytochem. 1987 Feb;35(2):139-48.

PMID:
3540102
27.

Expression of common acute lymphoblastic leukemia-associated antigen on germ cell tumor.

Brox AG, Lavallee MC, Arseneau J, Langleben A, Major PP.

Am J Med. 1986 Jun;80(6):1249-52.

PMID:
2942034
28.

Relationship between incorporation of 9-beta-D-arabinofuranosyladenine in L 1210 DNA and cytotoxicity.

Kufe DW, Major PP, Munroe D, Egan M, Herrick D.

Cancer Res. 1983 May;43(5):2000-4.

29.

Clinical pharmacology of arabinofuranosyladenine in combination with deoxycoformycin.

Major PP, Agarwal RP, Kufe DW.

Cancer Chemother Pharmacol. 1983;10(2):125-8. No abstract available.

PMID:
6600984
30.
31.

Effect of ARA-C incorporation on deoxyribonucleic acid synthesis in cells.

Major PP, Egan EM, Herrick DJ, Kufe DW.

Biochem Pharmacol. 1982 Sep 15;31(18):2937-40.

PMID:
7138584
32.

Simple and rapid high-performance liquid chromatographic method for analysis of nucleosides in biological fluids.

Agarwal RP, Major PP, Kufe DW.

J Chromatogr. 1982 Sep 10;231(2):418-24. No abstract available.

PMID:
7130318
33.

5-Fluorouracil incorporation in DNA of human breast carcinoma cells.

Major PP, Egan E, Herrick D, Kufe DW.

Cancer Res. 1982 Aug;42(8):3005-9.

34.

Instability of (ara-C) DNA under alkaline conditions.

Major PP, Egan EM, Herrick D, Kufe DW.

Biochem Pharmacol. 1982 Mar 1;31(5):861-6.

PMID:
7200770
35.

Modulation of 5-FU metabolism in human MCF-7 breast carcinoma cells.

Major PP, Egan EM, Sargent L, Kufe DW.

Cancer Chemother Pharmacol. 1982;8(1):87-91.

PMID:
7094201
36.

Studies on the mechanism of action of cytosine arabinoside.

Kufe DW, Major PP.

Med Pediatr Oncol. 1982;10 Suppl 1:49-67.

PMID:
6761569
37.
38.

5-Fluoro-2'-deoxyuridine incorporation in L1210 DNA.

Kufe DW, Major PP, Egan EM, Loh E.

J Biol Chem. 1981 Sep 10;256(17):8885-8.

39.

Correlation of thymidine-enhanced incorporation of ara-C in deoxyribonucleic acid with increased cell kill.

Major PP, Sargent L, Egan EM, Kufe DW.

Biochem Pharmacol. 1981 Aug 15;30(16):2221-4. No abstract available.

PMID:
7295337
40.

Clinical pharmacology of deoxycoformycin.

Major PP, Agarwal RP, Kufe DW.

Blood. 1981 Jul;58(1):91-6.

PMID:
6263381
41.

Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA.

Major PP, Egan EM, Beardsley GP, Minden MD, Kufe DW.

Proc Natl Acad Sci U S A. 1981 May;78(5):3235-9.

42.

Deoxycoformycin: neurological toxicity.

Major PP, Agarwal RP, Kufe DW.

Cancer Chemother Pharmacol. 1981;5(3):193-6.

PMID:
6975188
43.

A blast subclone of the HL-60 human promyelocytic cell line.

Major PP, Griffin JD, Minden M, Kufe DW.

Leuk Res. 1981;5(4-5):429-30. No abstract available.

PMID:
6945469
44.

Correlation of cytotoxicity with incorporation of ara-C into DNA.

Kufe DW, Major PP, Egan EM, Beardsley GP.

J Biol Chem. 1980 Oct 10;255(19):8997-900.

45.

Pulmonary fibrosis following therapy with melphalan: report of two cases.

Major PP, Laurin S, Bettez P.

Can Med Assoc J. 1980 Aug 9;123(3):197-202. No abstract available.

46.

Isolation of herpes simplex virus type 1 from lesions of erythema multiforme.

Major PP, Morisset R, Kurstak C, Kurstak E.

Can Med Assoc J. 1978 Apr 8;118(7):821-2. No abstract available.

Supplemental Content

Loading ...
Support Center